Herclon is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2. HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity. This joining leads to antibody mediated and leads to HER2 positive cells break down. Herclon is a intermediary of anti-body dependent cellular cytotoxicity. Distribution: Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine. Metabolism: As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes. Excretion: Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx 4 days as trastuzumab emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
Herclon is administer into vein through IV infusion over 90 minutes Do not administer IV push or bolus. Duration of Herclon is administrated in once every week or every 3 weeks. Before starting treatment, patients should undergo biopsy to check Herclon is the right regimen The infusion solution should be compatible to polyvinyl chloride or polyethylene bags. After dilution, the infusion bag should be stored at 2oC to 8oC for not more than 24 hours before use.
Brand : Herclon
Ingredients : Trastuzumab
Strength : 440mg
Manufactured : Roche
Package : two vials in a carton, one vial containing drug Transtuzumab & one vial containing bacteriostatic water
Cardiomyopathy Infusion reactions Embryo fetal toxicity Pulmonary toxicity Chemotherapy induced neutropeniaThe most common side effects
Hypertension Influenza Dyspnae URI Rhinitis Pharyngolaryngeal pain Sinusitis Epitasis Pulmonary hypertension Dizziness Decrease LVEF Palpitations Arrhythmia Cardiac failure Cough Interstitial pneumonitis Diarrhea/constipation Nausea, vomiting Dyspepsia Autoimmune thyroiditis Neutropenia Hypokalemia Anemia Thrombocytopenia Febrile neutropenia Renal failure Abdominal pain Arthralgia Back pain Bone pain Headache Paresthesia 1Rash Nail disorders Pruritus Pyrexia Chills Edema Asthenia Sudden death
Herclon is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatmentCardiomyopathy
Herclon receiving patients have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuePulmonary toxicity
Some serious fatal cases of pulmonary toxicity occur during Herclon treatment.Infusion reactions
During Herclon treatment some life threatening infusion reactions are produced. In serious infusion reactions, Stop the Herclon treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Herclon treatment.use with Caution.Therapy induced neutropenia
Higher incidence of neutropenia occurs during Herclon treatment.